Andrew Callos, Executive Vice President, Chief Commercial Officer, on August 31, 2026, sold 10,000 shares in Cytokinetics (CYTK) for $702,400. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1061983/000106198326000090/xslF345X05/form4.xml